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Abstract
Recent work has stimulated interest in the use of exosomes as nanocarriers for delivery of small 
drugs, RNAs, and proteins to the central nervous system (CNS). To overcome the blood-brain 
barrier (BBB), exosomes were modified with brain homing peptides that target brain endothelium 
but likely to increase immune response. Here for the first time we demonstrate that there is no 
need for such modification to penetrate the BBB in mammals. The naïve macrophage (Mϕ) 
exosomes can utilize, 1) on the one hand, the integrin lymphocyte function-associated antigen 1 
(LFA-1) and intercellular adhesion molecule 1 (ICAM-1), and, 2) on the other hand, the 
carbohydrate-binding C-type lectin receptors, to interact with brain microvessel endothelial cells 
comprising the BBB. Notably, upregulation of ICAM-1, a common process in inflammation, 
promotes Mϕ exosomes uptake in the BBB cells. We further demonstrate in vivo that naïve Mϕ 
exosomes, after intravenous (IV) administration, cross the BBB and deliver a cargo protein, the 
brain derived neurotrophic factor (BDNF), to the brain. This delivery is enhanced in the presence 
of brain inflammation, a condition often present in CNS diseases. Taken together, the findings are 
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of interest to basic science and possible use of Mϕ-derived exosomes as nanocarriers for brain 
delivery of therapeutic proteins to treat CNS diseases.
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INTRODUCTION
Exosomes are 40 to 200 nm membrane-encased vesicles secreted by cells via fusion of 
multivesicular bodies with cell plasma membranes. They contribute to intercellular 
communication by carrying proteins and RNAs between neighboring cells or even to distant 
organs, and were clinically evaluated as cancer vaccines. Tumor-derived exosomes loaded 
with curcumin were previously shown to accumulate in microglial cells and alleviate brain 
inflammation [1]. Moreover, Mϕ-derived exosomes loaded with catalase produce 
neuroprotection in a Parkinson’s disease (PD) mouse model [2]. Both studies employed an 
intranasal route of administration, which in theory allows substances to bypass the BBB and 
directly enter the brain with minimum blood exposure. However, it is unclear if these 
exosomes access the brain directly or indirectly via absorption into blood and subsequent 
blood to brain transport. Nonetheless, the percentage of injected dose reaching the brain 
following intranasal delivery is usually lower than 1% and can be as low as 0.1% or even 
less [3]. Furthermore, this administration route has high variability in the dose reaching the 
brain due to variability in drug disposition and is limited by the drug amounts that can be 
delivered in humans [4]. A systemic, for example, IV administration route enables direct 
access to the BBB and uniform brain distribution through the brain capillaries. However, 
brain bioavailability of ~ 98% of small- molecule drugs and almost all biomacromolecules is 
very poor [5, 6]. To address BBB penetration, exosomes from dendritic cells (DCs) [7] and 
human embryonic kidney 293T cells [8] were decorated with the brain targeting peptide 
(rabies virus glycoprotein). These modified exosomes delivered siRNA and silenced in the 
brain a gene of relevance to Alzheimer’s disease (AD) [7] and morphine relapse [8]. 
Unfortunately, such peptide-decorated exosomes can cause immune response, especially 
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during chronic treatments. The immunogenicity of the targeting peptide alone is likely low. 
However, exosomes present major histocompatibility complex (MHC) molecules and a co-
stimulatory molecule CD86 on the surface, which can potentially boost the immune 
response, especially with chronic exposure [9, 10]. Naïve exosomes released from brain 
endothelial cells were shown to penetrate the BBB, delivering a fluorescent marker and a 
chemotherapeutic agent, doxorubicin, to the brain in Zebrafish [11]. Therefore, it is crucial 
to investigate whether naïve exosomes could penetrate the BBB in preclinical animal 
models, such as rodents and primates.
We examined the possibility of utilizing naïve Mϕ exosomes as drug carriers for CNS. Our 
rationale is based on prior experience using Mϕs as cell carriers to treat CNS disorders [12–
14]. Pathology of many neurologic disorders, including multiple sclerosis, AD, PD, stroke, 
brain tumors, traumatic brain injuries, and others can result in BBB dysfunction [15]. The 
inflammatory processes associated with some of these pathologies can increase diapedesis of 
peripheral immune cells across the BBB [16]. Gendelman’s group used Mϕs as carriers for 
nanoformulated antiretroviral therapy for human immunodeficiency virus type 1 (HIV-1)-
associated neurocognitive disorders [17]. We used Mϕs as carriers for systemic delivery of 
the nanoformulated therapeutic proteins and genes to the inflamed brain in the PD models 
[12–14]. The functional activity of Mϕs in these applications can be in part mediated by 
exosomes that share common elements, such as LFA-1 involved in the diapedesis of Mϕs 
across endothelial barriers [18]. The Mϕ exosomes can mediate the transfer of their cargo to 
other brain resident cells [12, 14, 19, 20], or facilitate spreading of viruses and virus proteins 
from periphery to and within the brain [21, 22].
MATERIALS and METHODS
Materials
Fetal bovine serum (FBS), penicillin-streptomycin, Dulbecco’s modified eagle medium 
(DMEM), 0.25 % trypsin/EDTA, chemically defined lipid concentrate, HEPES (1M), CM-
DiI, protein G magnetic beads, Illustra Nap-5 columns, G418 sulfate, Alexa Fluor 488-
Transferrin(Tf), Alexa Fluor 488-Cholera toxin subunit B (CTB), and SlowFade® Gold 
antifade mountant were from Life Technologies (Grand Island, NY). Rat collagen I (lower 
viscosity) and Anti-Human DEC-205 antibodies were from R&D systems (Minneapolis, 
MN). Endothelial cell growth EBM-2medium was from Lonza (Basel, Switzerland). Goat 
anti-Alix, goat anti-Tsg 101, goat anti-LFA-1 and rabbit anti-ICAM-1antibodies were from 
Santa Cruz (Dallas, Texas). Rat anti-LAMP-2, rabbit anti-clathrin heavy chain antibodies 
was from Abcam (Cambridge, MA). Rabbit anti-caveolin-1 antibodies were from Cell 
Signaling (Danver, MA). Na125I and Na131I were from Perkin-Elmer Life Sciences (Boston, 
MA). Formvar coated copper grid (200 meshes), M-per mammalian protein extraction 
reagent, Micro BCA protein assay kit, agarose, HALT™ proteinase and phosphatase 
inhibitor cocktail and ECL western blotting substrate were purchased from Thermo Fisher 
Scientific (Rockford, IL). BDNF was purchased from PeproTech (Rocky Hill, NJ). 4–15% 
polyacrylamide gel, native sample buffer, and laemmli sample buffer were purchased from 
Bio-Rad (Hercules, CA). Human basic fibroblast growth factor (bFGF), hydrocortisone, 
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FITC-dextran conjugates (70 kDa) and lipopolysaccharides (LPS) and all other chemicals 
were from Sigma-Aldrich (St-Louis, MO).
Cell Culture
Raw 264.7 Mϕs (RAW Mϕs, American Type Culture Collection ATCC® TIB-71TM, 
Rockville, MD) between passage 1 and 30 were used. The cells were grown in DMEM 
medium plus 10% FBS and 1% penicillin-streptomycin, and subcultured by scraping. The 
conditioned medium for exosome collection was DMEM plus 1% penicillin-streptomycin 
and 10% FBS pre-centrifuged at 120 kg for 140 min to remove serum exosomes. 
hCMEC/D3 cells (a kind gift from Dr. Pierre-Olivier Couraud in Cochin Institute, France) 
between passage 30 and 35 were used. All cell cultureware for hCMEC/D3 cells was coated 
with 0.15 mg/ml rat collagen I. The cells were grown in EBM-2 containing 5% FBS, 1% 
Penicillin-Streptomycin, 1.4 µM hydrocortisone, 5µg/ml acid ascorbic, 100× diluted 
chemically defined lipid concentrate, 10 mM HEPES and 1 ng/ml bFGF. NIH-3T3 cells 
stably transfected with TrkB receptors (a kind gift from Dr. David Kaplan in University of 
Toronto, Canada) was cultured in DMEM supplemented with 10% Colorado Calf serum and 
100 µg/ml of G418 sulfate.
Animals
All animal experiments were conducted under the approval of the University of North 
Carolina Institutional Animal Care and Use Committee. Six to eight weeks old male CD-1 
mice were purchased from Charles River Laboratories.
Purification of Exosomes
Exosomes were purified by the common sequential centrifugation method [7, 23]. Raw Mϕs 
were grown in 7 T75 flasks to reach 70–80% confluence. Following two phosphate-buffered 
saline (PBS) washes, the cells were cultured in 10 ml conditioned medium for 2 days. The 
medium was then collected and centrifuged sequentially at 300g for 15 min, 3,000g for 15 
min, 20,000g for 70 min, and filtered through 0.2 µm membrane filters to remove cells and 
large particles. Exosomes were pelleted at 120,000g for 70 min, washed by PBS to remove 
proteins, pelleted again, and then resuspended in 1 ml PBS. For cell uptake study, the 
exosomes were labeled with CM-DiI dyes (2 µg/ml) added to the medium before the first 
120,000g pelleting step. The exosome suspension was filtered through 0.22 µm membrane 
filters to sterilize and remove the dye precipitate and stored in −80 °C for at most 3 weeks. 
Each batch of exosomes contained around 65 µg exosomal proteins as determined by 
microBCA and 3×1011 exosomes as determined by nanoparticle tracking analysis (NTA).
Characterization of Exosomes
Exosomes were characterized by dynamic light scattering (DLS) for intensity-weighted z-
average diameter, polydispersity index (PDI), and zeta potential, by NTA for number-
weighted diameter and particle concentration, and by transmission electron Microscopy 
(TEM) for morphology. For DLS, the size was measured in PBS, and the zeta- potential was 
measured in 10 mM NaCl at 23 °C with a 173° scattering angle using Zetasizer Nano-ZS 
instrument (Malvern, UK) in at least triplicates. For NTA, each sample was diluted 500 
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times in PBS and loaded into Nanosight NS500 (Malvern, UK). Three videos of 60s with a 
sample advance in between were recorded with the minimal expected particle size, 
minimum track length and blur setting all set to automatic. For TEM, exosomes were 
adsorbed onto Formvar coated copper grid (200 mesh), stained with 2% uranyl acetate and 
characterized using Zeiss TEM 910 Transmission Electron Microscope (Jena, Germany) at 
80 kV accelerating voltage.
Protein Composition and Exosomal Markers
Mϕs and Mϕ exosomes were lysed with RIPA buffer mixed with proteinase and phosphatase 
inhibitor cocktail. Protein composition and exosomal markers were detected by standard 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blotting under reducing condition [23].
Cell Viability
Cell viability was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5- diphenyltetrazolium 
bromide (MTT) assay. hCMEC/D3 cells were seeded in 96-well plates at 2000 cells/well in 
culture medium. After overnight incubation, the cells were treated with test agents in culture 
medium for time durations indicated in figure legend, and let grown in fresh culture medium 
(200 µl) for another 72 h. 20 µl of MTT in PBS (5 mg/ml) was added to each well. After 4h 
incubation at 37 °C, the formed formazan precipitate was dissolved in 150 µ l of DMSO. 
Absorbance at 570 nm (A) was read on a microplate reader SpectraMax M5 (Molecular 
devices). Blanks (wells without cells) that account for solvent adsorption and controls (wells 
with cells without test agents) for 100% viability were treated similarly. Cell viability (%) 
was calculated as . Data are means ± SD 
of 6 replicate wells.
Flow Cytometry
hCMEC/D3 cells were grown in 24-well plate at 5×104 cells/well for 4–5 days to reach 
confluence. In the uptake mechanism studies, the cells were pretreated with endocytosis 
inhibitors, carbohydrates or EGTA for 0.5 h, and then co-treated with CM-DiI labeled 
exosomes (0.6×1010 exosomes/ml) for 4 h. The inhibition of endocytosis markers uptake 
was studied similarly. The endocytosis markers used were Alexa Fluor 488-Transferrin (10 
µg/ml) for clathrin mediated endocytosis, Alexa Fluor 488-CTB (5 µg/ml) for caveolae 
mediated endocytosis, and FITC-Dextran (70 kDa (10 mg/ml) for macropinocytosis. The 
antibody block assays were done by co-incubating exosomes with antibodies or isotope 
controls at 100 µg/ml for 4 h. The cells were washed thrice by PBS, detached by 0.25% 
trypsin/EDTA, collected by centrifugation at 100 g for 10 min, fixed with 4% 
paraformaldehyde for 10 min, and then resuspended in 0.35 ml PBS. Viable singlets were 
gated based on forward scatter and side scatter. 5,000–10,000 viable singlets were recorded 
for each sample on Becton Dickinson LSRII (BD Biosciences) using 488 nm and 532 nm 
lasers. Unless otherwise noted in figure legend, data are not normalized and reported as 
mean fluorescence intensity (MFI) ± SD of 3 replicate wells.
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Laser scanning confocal microscopy (LSCM)
hCMEC/D3 cells were cultured in 35 mm glass bottom dishes at 1×105 cells/well for 5–6 
days to reach confluence. In endocytosis pathway studies, the cells were treated with CM-
DiI labeled exosomes (1×1011 exosomes/ml) and Alexa Fluor 488-Transferrin (25 µ g/ml) or 
Alexa Fluor 488-CTB (5 µg/ml) for 0.5 h, and then fixed before imaging. In the 
immunofluorescence studies, the cells were treated with CM-DiI labeled exosomes (1×1011 
exosomes/ml) for 0.5 h, fixed by 4% paraformaldehyde, blocked with 10% goat serum/0.3% 
Triton® X-100 in PBS at 23 °C for 1 h, and incubated with anti-clathrin heavy chain or anti-
caveolin 1 antibodies in 1% goat serum/1% BSA/0.3% Triton® X-100 in PBS at 4 °C 
overnight. Followed three washes using 0.1% BSA in PBS, the cells were incubated with 
Alexa Fluor 488 conjugated secondary antibodies, washed trice and mounted in SlowFade® 
Gold antifade mountant (Life technologies). Images were collected by Zeiss CLSM 700/710 
spectral confocal laser scanning microscope (Jena). Mander’s colocalization coefficients 
were calculated using Image J and JACoP plugin [24, 25].
Native gel electrophoresis
Protein samples were mixed with equal volume of native sample buffer (Bio-Rad), and then 
resolved on 4–15% polyacrylamide gel (Bio-Rad) in 25 mM Tris-Cl/250 mM glycine, pH 
8.5 at 120 v for 55 min, or on 0.5% horizontal agarose gel in 40 mM Tris/20 mM acetic 
acid/1 mM EDTA, pH 7.6 at 80 v for 50 min. The gels were stained with coomassie blue 
G250, and scanned using FluorChem E System (ProteinSimple).
Radioactive Labeling
Exosomes and BDNF/BSA proteins were labeled with iodine by chloramine-T method [26]. 
For this study, we collected Mϕ exosomes after 12 h incubation of Mϕ in DMEM to exclude 
iodination of serum proteins that could be co-precipitated during isolation of exosomes by 
ultracentrifugation. Briefly, exosomes or proteins were mixed with 1 mCi of Na125I or 
Na131I (Perkin Elmer) and 10 µ g of chloramine-T in phosphate buffer (0.25 M, pH 7.5) for 
60 s. Labeled exosomes and proteins were purified by Illustra Nap-5 columns (Life 
technologies) and collected in tubes pretreated with 1% BSA in PBS to prevent nonspecific 
adsorption. The iodine association (iodine in labeled sample/total iodine) was determined by 
trichloroacetic acid precipitation method [26]. Briefly, 1 µl of purified samples was mixed 
with 0.5 ml of 1% BSA in PBS and 0.5 ml of 30% TCA, and then centrifuged at 5400 g for 
10 min. The resulted pellet and supernatant were counted on r-counter (PerkinElmer). The 
iodine association was calculated as the percentage of pellet radioactivity to total 
radioactivity. The iodine association for exosomes and BSA/BDNF was higher than 85% 
and 98%, respectively. In the brain perfusion study, BSA was labeled with Technetium-99m 
(99mTc). In detail, 120 µ g of stannous tartrate and 1 mg of BSA were dissolved in 500 µl of 
water. The pH was adjusted to 2.5-3.3 by adding 20 µl of 0.2 M HCl, and then 1 mCi 
of 99mTc was added to the solution. The mixture was incubated at 23 °C for 20 min and then 
purified similarly as the iodinated proteins.
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Mice were anesthetized with 40% urethane (4 g/kg) by intraperitoneal injection. 125I-labeled 
substances (4×105 cpm) and 131I-labeled BSA were co-injected to the right jugular vein. At 
each time point, blood was collected from the left carotid artery, allowed to clot and then 
centrifuged at 5400 g for 10 min to collect serum. The mouse was immediately decapitated 
after collection of the arterial blood and the whole brain and peripheral organs removed and 
weighed immediately after decapitation. The radioactivity of serum and tissues were counted 
and normalized to injected dose (ID) by volume (ml) or weight (g) (%ID/ml or %ID/g). An 
injection check representing ID was also counted (n=3).
Pharmacokinetic analysis
The noncompartmental PK parameters - the volume of distribution at steady state Vss (ml), 
clearance CL (ml/min), the mean residence time from the time of dosing to last detectable 
concentration MRTlast (h) and the mean residence time from the time of dosing to infinity 
MRTinf (h) were estimated using Phoenix®WinNonlin® 6.3 (Pharsight).
Multiple-time regression analysis of influx into the brain
The Ki (slope) and Vi (y-intercept) were calculated from the linear portion of multiple-time 
regression analysis [27]. Brain/serum ratios ( , ml/g) of co-injected BSA were used 
to correct for the vascular space or leakage [28], and subtracted from that of the test 
substance to yield the delta brain/serum ratios. The delta brain/serum ratios were plotted 
against their respective exposure times using the equation
, where the exposure time  was the trapezoidal integral of serum cpm at time 
t (Cpt) from time 0 to time t divided by Cpt.
Brain accumulation
Brain accumulation of test substance (%ID/g) was calculated by multiplying the delta brain/
serum ratio (ml/g) with serum concentration (%ID/ml) at selected time point.
Capillary depletion
Capillary depletion was performed to determine whether the injected substances cross the 
capillary walls and enter the brain parenchyma as previously reported [28]. 10 min after 
injection, serum and brain samples were collected as mentioned above. The brain was 
homogenized in 1.25 ml of physiological buffer containing 10 mM HEPES, 141 mM NaCl, 
4 mM KCl, 2.8 mM CaCl21 mM MgSO41 mM NaH2PO4and 10 mM D-glucose, pH 7.4, 
and then mixed with equal volume of 40 % Dextran (70 kDa, Sigma) by vortex. The mixture 
was centrifuged at 3500 g for 20 min at 4 °C. The radioactivity of the capillary pellet, 
parenchyma supernatant, and serum was counted. The delta capillary/serum ratio and 
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parenchyma/serum ratio of 125I-labeled test substance was corrected using 131I-BSA data, 
and then multiplied by the serum concentration to calculate the uptake (%ID/g) in brain 
capillary and parenchyma.
Brain perfusion
The mice were treated with intraperitoneal injection of saline (healthy mice) or LPS in saline 
(3 mg/kg, a brain inflammation model) at 0, 6, and 24 h. At 28 h, the mice were anesthetized 
by intraperitoneal injection of urethane. The brain perfusion was done by clamping the 
descending aorta, cutting the jugular vein, and then injecting the perfusion solution into the 
heart. The mouse brains were perfused with 125I-labeled exosomes and 99mTc-labeled BSA 
(as a vascular marker) in lactated ringer’s buffer containing 1% unlabeled BSA (to prevent 
nonspecific binding) at 2 ml/min for 2.5 min. The radioactivity in brain and in perfusion 
buffer was counted simultaneously and normalized by weight and by volume. The brain/
perfusion ratio of BSA was subtracted from the ratio of exosomes to account for BBB 
leakiness.
Statistical analysis
Statistical analysis was performed using Prism 6.0 (GraphPad Software Inc.) unpaired two-
tailed student t-test (# p < 0.05, ## p < 0.01, and ### p < 0.001), paired two- tailed student t-
test(& p < 0.05, && p < 0.01, and &&& p < 0.001), or one-way ANOVA with post 
Newman-Keuls multiple comparison test (* p < 0.05, ** p < 0.01, and *** p < 0.001) as 
indicated in the figure legend.
RESULTS AND DISCUSSION
Mϕ exosomes are natural nanoparticles
We hypothesized that Mϕ-derived exosomes can naturally bind with brain endothelial cells, 
pass across the BBB and enter the brain. To test this hypothesis, we collected exosomes 
secreted by RAW Mϕs by the sequential centrifugation method [7, 23]. We characterized 
their size distribution and zeta potential by DLS (Figure S1a, b) and NTA (Figure 1a), 
morphology by TEM (Figure S1c), and protein composition by SDS- PAGE (Figure S1d) 
and western blotting (Figure 1b). Consistent with published results [7, 29], Mϕ exosomes 
were heterogeneous in size with an intensity-weighted z-average diameter of 149 ± 10 nm, a 
relatively small PDI of 0.134 ± 0.048 as determined by DLS, and a number-weighted mean 
diameter of 130 ± 49 nm, a mode diameter of 90 ± 2 nm by NTA. Mϕ exosomes were 
negatively charged (zeta potential −18 ± 1 mV) in 10 mM NaCl. TEM showed spherical 
morphology as published [23]. Occasionally, we observed aggregation and cup-shaped 
nanovesicles (insert of Figure S1c) as an artifact of sample drying [23]. Based on SDS-
PAGE, the protein composition of exosomes differed from both the parent Mϕs and FBS 
[23]. As revealed using western blotting, compared to Mϕs, exosomes were enriched with 
apoptosis- linked-gene-2 interacting protein X (Alix) and tumor susceptibility gene 101 
protein (Tsg 101), two exosomal markers related to the biogenesis of multivesicular bodies 
[21]. Mϕ exosomes also contained a transmembrane protein lysosome-associated membrane 
protein 2 (LAMP 2) and a cytosolic protein β-actin that are frequently detected in exosomes 
[21].
Yuan et al. Page 8













Uptake of Mϕ exosomes in human cerebral microvascular endothelial cells
Next, we characterized the interactions of Mϕ exosomes with human cerebral microvascular 
endothelial cells (hCMEC/D3) as an in vitro BBB model. The MTT assay showed that the 
viability of these cells was not affected by their exposure to Mϕ exosomes for 24 h up to the 
highest tested concentration of 2×1011 exosomes/ml (Figure S2a, b). All subsequent studies 
involving hCMEC/D3 cells used lower concentrations of exosomes. We labeled exosomes 
with the lipophilic dye CM-DiI to monitor their uptake by hCMEC/D3 cells. CM-DiI 
labeling did not significantly change the size distribution and zeta-potential of exosomes as 
determined by DLS (the intensity-based diameter of CM-DiI labeled exosomes was 166 
± 18 nm, PDI 0.139 ± 0.03, and zeta potential −18 ± 5 mV). After an initial lag period of 4 
h, the amount of Mϕ exosomes in hCMEC/D3 cells increased in a linear fashion over 48 h 
(Figure S2c). Incubation at 4 °C completely blocked the uptake of Mϕ exosomes (Figure 
S3a), suggesting that their internalization in hCMEC/D3 cells is an energy-dependent 
process.
To dissect the endocytosis pathways, we pre-incubated hCMEC/D3 cells with endocytosis 
inhibitors for 0.5 h, and then co-incubated with fresh inhibitors and Mϕ exosomes for 
another 4 h. We selected hyperosmolar sucrose [30], nystatin [30], and 5-(N-Ethyl-N-
isopropyl) amiloride (EIPA) [31] as the inhibitors for clathrin-mediated endocytosis, 
caveolae-mediated endocytosis, and macropinocytosis, respectively. Each inhibitor, at non-
toxic concentrations, diminished uptake of a corresponding endocytosis marker (transferrin, 
CTB, and dextran) (Figure S3 b, c, d, and S4). Each of these inhibitors also decreased the 
uptake of Mϕ exosomes (Figure S3a), suggesting that these exosomes, similar to exosomes 
derived from tumor or immune cells [32], utilize multiple pathways (including clathrin, 
caveolae, and macropinocytosis) to enter the endothelial cells. Involvement of clathrin and 
caveolae pathways was further supported by colocalization of Mϕ exosomes with transferrin, 
anti-clathrin heavy chain antibodies, CTB, and anti-caveolin 1 antibodies (Figure S5). The 
cellular uptake of Mϕ exosomes displayed saturation at high exosome concentrations (Figure 
1c) and was inhibited by unlabeled exosomes in a concentration-dependent fashion (Figure 
1d). This suggested a possibility of saturable receptor interactions and we therefore 
examined the molecular mechanisms involved.
ICAM-1/LFA-1 mediated uptake of Mϕ exosomes in hCMEC/D3 cells
The interactions between an integrin LFA-1 and ICAM-1 were previously implicated in the 
uptake of Mϕ exosomes in umbilical vein endothelial cells [33]. The LFA-1 and ICAM-1 
were indeed expressed in our Mϕ exosomes and hCMEC/D3 cells, respectively (Figure 2a, 
b). The ICAM-1 was upregulated by treating hCMEC/D3 cells with LPS (Figure 2b), which 
mimics the response of brain endothelial cells to inflammation [34], and was accompanied 
by the increased accumulation of exosomes in the cells (Figure 2c). Moreover, each of anti-
ICAM-1 or anti-LFA- 1 antibodies and their combination inhibited the exosome uptake 
(Figure 2d), suggesting that both LFA-1 and ICAM-1 play an important role in the uptake of 
Mϕ exosomes in brain endothelial cells.
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C-type lectin receptors mediated uptake of Mϕ exosomes in hCMEC/D3 cells
During the endocytosis inhibition studies (Figure S3), we noted that sucrose had a more 
profound inhibitory effect on the cell uptake of Mϕ exosomes than that of transferrin. 
Therefore, we hypothesized that some additional carbohydrate binding receptors may be 
involved in the uptake of exosomes. The possible candidates are the C-type lectin receptors 
that require binding of calcium for their carbohydrate-binding activity [35]. It was reported 
that DCs-derived exosomes are internalized into recipient cells partially by mannose/
glucosamine-binding C-type lectin receptors, as was demonstrated by a blocking assay using 
DEC205 antibodies, the calcium chelator ethylenediaminetetraacetic acid (EDTA), and a 
panel of monosaccharides, including mannose and glucosamine [35]. We confirmed the 
presence of lectin receptors in hCMEC/D3 cells by western blotting using DEC205 
antibodies (Figure 3a and Figure S6). Furthermore, the accumulation of Mϕ-derived 
exosomes in hCMEC/D3 cells was decreased by a panel of carbohydrates, the calcium 
chelator ethylene glycol-bis(2-aminoethylether)-N, N, N’, N’- tetraacetic acid (EGTA), and 
DEC205 antibodies (Figure 3b, c, d). Among the carbohydrates, glucosamine inhibited the 
uptake of exosomes at much lower concentrations, suggesting that the inhibitory effect 
differed from the hyperosmotic effect of sucrose that blocked endocytosis [36]. It was 
reported that some carbohydrates, for example glucosamine, inhibit ICAM-1 expression in 
rat cardiomyocytes [37] and human retinal pigment epithelial cells [38]. We tested this 
possibility and demonstrated that even at the highest concentrations used, glucose and 
glucosamine did not inhibit the expression of ICAM-1 in our cell model (Figure S7). 
Therefore, in addition to ICAM-1, specific carbohydrate binding receptors, especially 
glucosamine-binding C-type lectin receptors, mediate the accumulation of Mϕ-derived 
exosomes in hCMEC/D3 cells. The LPS stimulation did not enhance expression of lectin 
receptors in hCMEC/D3 cells (Figure S8), suggesting that, in contrast to ICAM-1, these 
receptors are not involved in the increased uptake of Mϕ exosomes in response to LPS 
stimulation.
Pharmacokinetics (PK) and distribution of Mϕ exosomes in healthy mice
Next, we characterized the PK and distribution of Mϕ exosomes in healthy CD-1 mice after 
IV injection of 125I-radiolabeled Mϕ exosomes along with 131I-labeled bovine serum 
albumin (BSA) as a vascular marker [39]. The labeled exosomes and BSA were separated 
from free iodine in a Nap- 5 column. We characterized the size distribution of exosomes 
before and after elution to evaluate if the labeling procedure changes the size distribution. 
The z-average diameter of exosomes was decreased to 116.2 ± 6.2 nm from 147 ± 8.3 nm 
after elution, suggesting that the size exclusion column removed the large particles. The 
clearance of both Mϕ exosomes and BSA showed a two-phase decay (Figure 4a). Their PK 
parameters are presented in Table S1. Similar to tumor-derived exosomes [40], Mϕ 
exosomes mainly accumulated in the liver and spleen at 10 min, 4 h, and 24 h (Figure 4b), 
suggesting entrapment of exosomes in the mononuclear phagocyte system (MPS) [41] or 
their binding with ICAM-1[42] and lectin receptors [43] expressed in liver and spleen. 
Accumulation of Mϕ exosomes in the brain at 10 min and 4 h was 0.093%ID/g, 
0.088%ID/g, and decreased to 0.05%ID/g at 24 h, suggesting a slow rate of clearance from 
the brain. Importantly, 94% of exosomes penetrated the brain accumulated in the 
parenchyma fraction in the capillary depletion assay (Figure S9).
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Neuroinflammation increased brain influx rate and brain accumulation of Mϕ exosomes
To examine whether the inflammation increases the homing of Mϕ-derived exosomes to the 
brain, we compared the PK of Mϕ exosomes in healthy mice and in mice with LPS- induced 
encephalitis, a mouse model of brain inflammation [44]. The clearances of exosomes and 
co-injected BSA in the brain-inflamed mice resembled those in the healthy mice (Figure 
S10a). Both healthy and brain-inflamed mice showed a significant net brain influx of 
exosomes (Figure 4c): the slopes (Ki) of the delta brain/serum ratios plotted against 
exposure time significantly deviated from zero (p < 0.05), thus demonstrating net brain 
influx. The unidirectional brain influx rate (Ki) and initial volume of brain distribution (Vi) 
of exosomes in the brain-inflamed mice were respectively 3- and 2-fold higher than those in 
the healthy mice. The plot of the delta brain/serum ratios against serum concentrations 
directly demonstrated increased accumulation of Mϕ-derived exosomes in the inflamed 
brains at similar serum concentrations of exosomes as in the healthy mice (Figure S10b). In 
addition, the brain influx rates of BSA in the brain-inflamed and healthy mice were 
comparable (p = 0.076, Figure S10c), suggesting that the increase in the brain influx of 
exosomes under inflammation was not caused by BBB disruption. Consistent with the 
increased brain influx rate, the brain accumulation of Mϕ exosomes in the inflamed brain at 
10 min was 5.8 fold higher than that in the healthy mice (Figure 4d). (The percentage of 
injected dose at 10 min is 0.093 ± 0.02 %D/g brain in healthy brain and 0.538 
± 0.315 %ID/g brain in inflamed brain. This corresponds to the percentage of injected dose 
of ~0.0372 ID% in healthy brain and ~0.215 ID% in inflamed brain calculated using the 
average mouse brain weight of 0.4 g.) Consistent with our in vitro finding of an increased 
accumulation of exosomes in LPS treated brain endothelial cells in response to increased 
ICAM-1 expression (Figure 2c), the in vivo brain penetration of exosomes increased during 
inflammation when ICAM-1 expression was upregulated (Figure S11). Due to the weak 
fluorescence of exosomes in brain, we were not able to confirm the colocalization of 
exosomes with ICAM-1. However, murine ICAM-1 and LFA-1 are highly homologous to 
human ICAM-1 [45, 46] and LFA-1 [47], thus the interaction of exosomal LFA-1 with 
human ICAM-1 demonstrated in vitro using human brain endothelial cells can be indicative 
of the in vivo interaction of exosomal LFA-1 with murine ICAM-1. The finding of exosome 
brain penetration mediated by an ICAM-1/LFA-1 interaction is likely to stand independently 
of the species and murine strain of the exosomes, endothelial cell model, and the animal 
model.
The increased brain penetration of exosomes under neuroinflammation has some 
commonality with the increased brain infiltration of Mϕs upon inflammation [16, 48]. To 
confirm that exosomes can penetrate the BBB independently of brain-infiltrating immune 
cells as we showed in vitrowe perfused the mouse brain with exosomes in physiological 
buffer in healthy mice and brain inflamed mice. In this brain perfusion study, we used 
another brain inflammation model, which was established by three intraperitoneal injections 
of LPS a day before the PK study as reported previously [28]. Peripheral inflammation 
which may divert exosomes to inflamed peripheral organs due to upregulation of ICAM-1 is 
not a concern as only the brain is perfused. The brain perfusion study excludes the potential 
involvement of an immune cell-mediated pathway, which involves endocytosis by immune 
cells and subsequent brain penetration via the cell carriers. In this setting, exosomes still 
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showed higher brain/perfusion ratio than a co-administered vascular marker BSA in both 
healthy mice and the brain inflammation model (delta brain/perfusion ratio is positive), 
suggesting that exosomes can penetrate the brain independently of infiltrating immune cells 
(Figure S12). In addition, the delta brain/perfusion ratio of exosomes in the brain 
inflammation model was significantly higher than that in the healthy mice, further 
supporting the aforementioned increased brain penetration of exosomes under 
neuroinflammation.
The mouse model of intracranial LPS-induced encephalitis also displayed significantly 
higher accumulation of Mϕ exosomes in the heart (1.6 fold), lungs (7.1 fold) and kidneys 
(3.9 fold) (Figure 4d). This could be explained by peripheral inflammation resulting from 
the absorption of LPS from the brain cerebrospinal fluid (CSF) to the blood [28] and/or 
activation of microglia and release of other inflammatory cytokines to the peripheral [49, 
50]. Zhou et al. showed that intracerebroventricular injection of LPS at a lower dose (2 µg) 
activates microglia as well as peritoneal macrophage, clearly suggesting that a peripheral 
inflammation process does occur after brain local injection of LPS [50].
The inflammation-responsive brain distribution of Mϕ exosomes is remarkable and provides 
a strong rationale for their potential application as natural nanocarriers for neurodegenerative 
disorders commonly accompanied with brain inflammation.
Mϕ exosomes delivered a protein cargo to the brain
To determine whether Mϕ exosomes could deliver cargo to the brain, we loaded them with 
the BDNF as a model protein by simply mixing exosomes and BDNF in 10 mM phosphate 
buffer (pH 7.4). The binding of BDNF (isoelectric point 9.99) [51] with the negatively 
charged exosomes (zeta potential −18 mV) by electrostatic and polysaccharide interactions 
[52, 53] formed a BDNF-exosome complex (ExoBDNF), which was confirmed by 
demonstrating 1) that exosomes are precipitated by Protein G-magnetic beads coupled with 
BDNF antibodies (Figure 5a) and 2) that exosomes prevent migration of BDNF into a native 
polyacrylamide gel (Figure 5b). The latter indicated that Mϕ-derived exosomes can capture 
as much as 20 % by weight of BDNF relative to its own protein. Characterized by DLS, the 
z-average diameter of exosomes, ExoBDNF, and BDNF in one batch were 147.0 ± 8.3 nm, 
209.5 ± 4.7 nm, and 36.1 ± 13.5 nm. The increase in diameter, the pull-down assay, and the 
native electrophoresis all support that BDNF can associate with exosomes by simple mixing. 
Interestingly, ExoBDNF released BDNF upon binding with the BDNF receptor TrkB, and 
the released neurotrophin was able to induce phosphorylation of receptor and downstream 
Akt signaling in NIH-3T3-TrKB cells (Figure S13).
We further determined whether Mϕ-derived exosomes facilitate BDNF transfer to the brain. 
In this experiment, we co-injected 131I- BSA and 125I-BDNF with or without exosomes into 
the jugular vein of healthy CD-1 mice. The brain/serum ratios of BDNF loaded onto 
exosomes were significantly higher than those BDNF alone (Figure 5c). To the contrary, the 
brain influx rates of co-injected BSA in both groups were comparable and did not differ 
from 0 (Figure 5d). The brain/serum ratios of BSA in both groups were similar as well 
(Figure S14). These data also indirectly suggested that BDNF at least in part remained with 
exosomes after administration in vivo. We also found that ExoBDNF complex was stable in 
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the presence of NaCl up to the highest tested concentration of 1 M (Figure S15). We further 
compared the brain accumulation of naked and exosome-formulated BDNF in healthy and 
brain-inflamed mice (Figure 5e). The brain accumulation of exosome-formulated BDNF in 
healthy mice was slightly but not significantly increased compared to BDNF alone (p = 
0.63). Brain inflammation resulted in a trend to increase the brain accumulation of free 
BDNF but the difference was not significant when compared to the healthy mice (p = 0.11). 
In contrast, accumulation of exosome-formulated BDNF (ExoBDNF) in the brain-inflamed 
mice was significantly increased compared to the same formulation in the healthy animals 
(3.6 fold). Moreover, the brain accumulation of BDNF with this formulation was also 
superior to that of the BDNF alone in the inflamed brain (2.2 fold). Importantly in the 
capillary depletion experiment, 89% and 95% of the BDNF accumulated in the brain 
distributed to the brain parenchyma in the BDNF alone group and ExoBDNF group (Figure 
5f), suggesting that both BDNF alone and BDNF in ExoBDNF group can penetrate the 
BBB. In addition, brain accumulation of ExoBDNF in the parenchyma fraction was 
significantly higher than BDNF alone in healthy mice. Note that we subtracted the serum 
contamination from both capillary and parenchyma fractions using co-injected BSA as in the 
tissue distribution study, however, the percentages of injected dose accumulated in 
parenchyma fractions (Figure 5f) were higher than the percentages in whole brain (Figure 
5e), which may suggest mass transfer of iodinated BDNF from serum fractions to 
parenchyma fractions during homogenization in the capillary depletion experiment likely 
due to enhanced adsorption to distorted cell membrane and/or extracellular matrix in brain 
parenchyma that is otherwise separated from blood by the brain endothelium. Note that 
BDNF can bind to extracellular matrix [52, 53]. Thus, we calculated the percentage of 
injected dose per gram of brain in the parenchyma fractions by subtracting the value in the 
capillary fractions (in Figure 5f, 0.014%ID/g for both groups) from the value in total brain 
(in Figure 5e) as a rough estimation, which yielded 0.024%ID/g for BDNF alone group and 
0.038%ID/g for ExoBDNF group. This calculation indicated that 63.2% and 73.1% of 
iodinated BDNF in brain distributed to the parenchyma in BDNF and ExoBDNF group. 
Nonetheless, the increased whole brain accumulation of BDNF upon mixing with exosomes 
suggests that even though the cargo was loaded onto the surface of exosomes, exosomes still 
preserve their brain penetration property.
CONCLUSION AND FUTURE DIRECTIONS
To summarize, we isolated exosomes from Raw Mϕs and characterized their interaction with 
immortalized human brain endothelial cells (hCMEC/D3 cells) in vitroand their PK in mice 
with or without brain inflammation. In vitro, we first showed that hCMEC/D3 cells 
internalized Mϕ exosomes in a saturable manner using multiple pathways (clathrin-/
caveolae-mediated endocytosis, and macropinocytosis), implying a possible receptor-
mediated pathway. We then confirmed that Mϕ-derived exosomes inherited LFA-1 from 
their parental cells, a protein that interacts with endothelial ICAM-1 and mediates the lateral 
migration and diapedesis of Mϕs across the BBB [18]. More importantly, the LFA-1 and 
ICAM-1 also mediated cellular uptake of Mϕ-derived exosomes in hCMEC/D3 cells. The 
cellular uptake of exosomes increased significantly under inflammation conditions in 
response to overexpression of ICAM-1 receptors on endothelial cells, resembling the 
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increased diapedesis of Mϕs across the BBB under inflammation. We also identified that 
cellular uptake of Mϕ-derived exosomes in hCMEC/D3 cells involves C-type lectin 
receptors, because various carbohydrates, a specific antibody, and calcium chelators blocked 
the accumulation. However, the C-type lectin receptors were not responsible for the 
increased cellular uptake under inflammation. In vivo, we demonstrated that IV administered 
Mϕ-derived exosomes penetrated the BBB to the brain parenchyma in healthy mice. 
Although these exosomes mainly distributed in the liver and spleen, they also accumulated 
in brain at a level as high as 0.093 ID%/g, and were slowly cleared from the brain. 
Consistent with increased cellular uptake under inflammation, Mϕ-derived exosomes entered 
the brain 3.1-fold faster and accumulated 5.8-fold greater in the inflamed brain than in the 
healthy brain, without increased accumulation in liver and spleen. We also demonstrated that 
Mϕ-derived exosomes can enter the brain independently without the help from brain 
infiltrating immune cells and that the increased accumulation in inflamed brain was due to 
enhanced exosome-brain endothelium interaction. Strategies to reduce uptake by the MPS 
organs such as PEGylation can be explored in the future to shield exosomes and extend 
circulation time in order to further improve brain accumulation. Furthermore, we loaded a 
model cargo protein radiolabeled BDNF onto Mϕ exosomes and showed that they 
successfully delivered BDNF to the brain parenchyma in healthy mice, and even at greater 
extent to the brain with inflammation (0.19 ID%/g).
Noteworthy, our findings contradict with the results reported by Hwang et al [54]. This 
report indicated that technetium-radiolabeled Mϕ exosomes and the Mϕ extruded membrane 
vesicles showed no detectable signal in the brain region of BALB/c mice by single photon 
emission computed tomography (SPECT) [54]. This discrepancy can be possibly explained 
by the higher sensitivity of iodine detection method and difference in size distribution. 
Compared to exosomes utilized in this investigation (130 nm), the Mϕ-derived extruded 
membrane vesicles had larger average diameter (218 nm), which may result in increased 
sequestration in peripheral organs causing lower brain transport. Besides, our study was 
consistent with the study showing that fluorescently labeled exosomes released from 
autologous dendritic cells was detectable in mouse brains 24 h after IV injection [55], and 
other recent study showing that HEK293T exosomes can penetrate the Transwell model of 
BBB transcellularly under inflamed conditions (TNF-α activated) [56].
Although we did not specifically evaluate the blood-CSF barrier (choroid plexus or 
ependymal barrier), our in vivo model can reflect an influence of that barrier. The vascular 
barrier is usually thought to be the preferred route for drug delivery because of its proximity 
to the neurons and the blood-CSF barrier is generally assumed to primarily inventory the 
vascular BBB [57–59], however, such a view can underestimate the importance of the 
choroid plexus. We showed in vitro that exosomes can be internalized into human brain 
endothelial cells. Therefore, we conclude that exosomes can penetrate the vascular barrier, 
but can make no conclusions regarding their ability to penetrate the blood-CSF barrier.
The Raw 264.7 Mϕ exosomes, which originate from BALB/c mice, were tested in a different 
murine strain (CD-1 mice). Possibly, these exosomes are cleared faster in CD-1 mice than in 
autologous BALB/c mice due to immune response. However, recent publications 
demonstrate that exosomes from different species (human, rat, or mouse) and exosomes 
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from different mouse strains all show rapid clearance and sequestration by MPS organs such 
as liver, spleen, and lung in mice [40, 54, 55, 60–62]. These data indicate that exosomes may 
not readily avoid the MPS sequestration as assumed from their wide existence in biological 
fluids and their “self” nature. If accelerated clearance in CD-1 mice did occur, we would 
expect higher brain uptake of these exosomes in BALB/c mice as a result of longer exposure 
to the BBB. As gender difference in inflammatory response [63] and in the brain 
transduction of adeno-associated virus serotype 9 has been reported, it would be interesting 
to investigate the potential gender influence in brain penetration of exosomes.
The ability of Mϕ exosomes to cross the BBB and ferry a cargo to the brain parenchyma 
especially under brain inflammation, a common condition associated with many CNS 
disorders [65], can be explored to deliver various disease-modulating proteins to the brain. 
The dose reaching the brain is generally low when compared to peripheral organs and tumor 
[66]. The brain bioavailability is often below 0.2 %ID/g brain and can be as low as 
0.01 %ID/g brain [66]. Considering the low brain bioavailability of exosomes under 
neuroinflammation, a choice of a highly potent therapeutic protein is beneficial. For 
instance, although the brain bioavailability of an anti-transferrin receptor/β-secretase 
bispecific antibody is less than 1 %ID/g brain, this bispecific antibody efficiently reduces the 
brain burden of amyloid β peptides [67]. Moreover one could expect that exosomes are safer 
than synthetic drug delivery systems due to the biological origin of exosomes. Another 
potential benefit of natural exosomes over artificial targeting drug carriers is the ease of 
manufacturing and scalability. One can engineer the genetically modified parent cells to 
continuously secret exosomes containing the desired therapeutic proteins. In principle, one 
could also implant the engineered parent cells in vivo to reduce the injection frequency. 
Moreover, exosomes mediated cargo transfer from transplanted Mϕs to contiguous brain 
resident cells such as endothelial cells and neurons [12, 14, 19, 20], and facilitated spreading 
of disease-relevant proteins inside the brain and into CSF [21, 22], suggesting exosomes 
may facilitate drug distribution in the brain upon penetrating the BBB.
Taken together, Mϕ-derived exosomes are promising nanocarriers for brain delivery of 
therapeutic proteins. These findings are of interest to basic understanding of possible role of 
exosomes in transfer and distribution of exogenous biological molecules as well as of 
significance to practical applications in drug delivery to CNS.
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Figure 1. Characterization of Mϕ exosomes
(a) Number-weighted size distribution of exosomes by NTA (different colors show three 
repeated measurements). (b) Western blotting of RAW Mϕs and exosome lysates at 
comparable protein loading amounts showing exosomal markers and conserved proteins. (c) 
Concentration-dependent uptake of CM-DiI labeled exosomes at 4 h. (d) Inhibition of 
uptake of CM-DiI labeled exosomes (0.6×1010 exosomes/ml at 4 h) by non-labeled 
exosomes. *** p < 0.001 vs untreated cells background (bkg) or indicated groups. Exosomes 
were purified by sequential centrifugation of RAW Mϕs-conditioned medium. Cell uptake 
was determined by Flow cytometry. Data are mean fluorescence intensity (MFI) ± SD of 
5000–10000 live singlets, n = 3, * p < 0.05 and *** p < 0.001 vs. untreated cells or indicated 
groups by one-way ANOVA and post Newman-Keuls multiple comparison test.
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Figure 2. ICAM-1/LFA-1 mediate uptake of Mϕ exosomes in hCMEC/D3 cells
(a) Expression of LFA-1 in Raw Mϕs and Mϕ-derived exosomes by western blotting at equal 
protein loading. (b) Expression of ICAM-1 in hCMEC/D3 cells in response to 3 or 6 h of 
stimulation with LPS (100 ng/ml). (c) Uptake of exosomes in hCMEC/D3 cells with or 
without 3 or 6 h of LPS stimulation. (d) Effect of co-incubation with anti-ICAM-1 or anti-
LFA-1 antibodies (100 µg/ml) on cell uptake of exosomes in hCMEC/D3 cells. Cell uptake 
was determined by flow cytometry after 4 h incubation with CM-DiI labeled exosomes 
(0.6×1010 exosomes/ml). Data are MFI ± SD of 5000–10000 live singlets, n = 3, * p < 0.05, 
** p < 0.01 and *** p < 0.001 vs. indicated groups by one-way ANOVA and post Newman-
Keuls multiple comparison test.
Yuan et al. Page 21













Figure 3. C-type lectin receptors mediate uptake of Mϕ-derived exosomes in hCMEC/D3 cells
(a) Expression of lectin receptors in hCMEC/D3 cells. Raw Mϕs and Mϕ-derived exosomes 
examined by western blotting at equivalent protein loading for C-type lectin receptor 
(DEC205) at non-reducing condition and β-actin at reducing condition. (b) Effect of 
carbohydrates on the uptake of exosomes. The carbohydrates were added to cells 0.5 h 
before and during incubation with exosomes. The data are normalized to the control cells 
treated with exosomes only. (c, d) Accumulation of exosomes in hCMEC/D3 cells in the 
presence of (c) EGTA and (d) DEC205 antibody (100 µg/ml). In (a, c, d) cells were exposed 
to CM-DiI labeled exosomes (0.6×1010 exosomes/ml) for 4 h and then analyzed by flow 
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cytometry. Data are MFI ± SD of 5000–10000 live singlets, n = 3, ***p < 0.001 by one-way 
ANOVA and post Newman- Keuls multiple comparison tests. The used concentrations of 
carbohydrates and EGTA ensured at least 80% cell viability (Figure S4).
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Figure 4. PK and distribution of Mϕ exosomes in healthy and brain-inflamed CD-1 mice
The brain inflammation in CD-1 mice was induced by intracranial injection of 10 µg LPS 24 
h before the exosome administration. The mice were co-injected with 125I-exosomes 
and 131I-BSA via jugular vein. (a) Clearance of exosomes and BSA in healthy mice. (b) 
Distribution of exosomes in healthy mice. (c) Multiple-time regression analysis of exosomes 
for brain influx rate in healthy and brain-inflamed mice. Delta brain/serum ratios were 
calculated by subtracting the brain/serum ratios of BSA from those of exosomes to correct 
for vascular space [28]. (d) Distribution of exosomes at 10 min. Tissue accumulation was 
corrected for vascular space using BSA data. Data are means ± SEM, n = 3-6. # p < 0.05, ## 
p < 0.01, and ### p < 0.001 vs. indicated group by unpaired two-tailed t-test.
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Figure 5. Formation and brain delivery of ExoBDNF complex
(a) ExoBDNF were isolated using protein G magnetic beads modified with BDNF-specific 
antibodies. The presence of LAMP 2 in the magnetic bead-separated fractions indicated that 
the exosomes were captured on the beads. A control group of exosomes without BDNF 
treatment was used to account for nonspecific binding. (b) Native PAGE of the mixtures of 
Mϕ exosomes and BDNF at different protein ratios. Exosomes prevented the neurotrophic 
factor migration in the gel toward the cathode up to a BDNF: exosomal protein weight ratio 
of 1:5. (c) Healthy mice were co-injected with 131I-BSA and 125I-BDNF with or without Mϕ 
exosomes via jugular vein. The brain/serum ratios at time points of 1, 2, 3, 4, 5, 6, 7.5, 10, 
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15, 20, 30 min were averaged. ### p < 0.001 by unpaired two-tailed t-test. (d) Multiple-time 
regression analysis of co-injected BSA in healthy mice. Both slopes are comparable to 0 
(p=0.064 for BSA and p=0.09 for BSA + Exosomes). (e) Brain accumulation of naked 
BDNF or BDNF in ExoBDNF in healthy or brain-inflamed mice at 10 min. Data are means 
± SEM, n = 4, ** p < 0.01 indicated group by one-way ANOVA and post Newman-Keuls 
multiple comparison test. (f) Distribution of BDNF or BDNF in ExoBDNF in brain 
parenchyma at 10 min in healthy mice determined by capillary depletion assay. Data are 
means ± SEM, n = 5, && p < 0.01 and &&& p < 0.001 by paired two-tailed t-test, ### p < 
0.001 by unpaired two-tailed t-test.
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